reported today:
"Two Phase III multinational clinical trials are currently being conducted with our PLX-PAD product candidate: one in CLI, and the other in
muscle recovery following surgery for hip fracture. In April 2019, we successfully enrolled over 50% of patients in our Phase III study in CLI, which
allows for an interim analysis of efficacy after a one-year follow-up period under the European Medicines Agency’s, or EMA, Adaptive Pathways
pilot project, or the Adaptive Pathways Project, in which PLX-PAD was selected to participate In December 2019, we successfully enrolled 75% of
the patients and, based on our current patient enrollment progress, we expect to complete the follow up of our Phase III study in CLI in the first half
of 2020 with respect to the European adaptive pathway, and in the first half of 2021 with respect to the United States"
Technically, a good chance for pattern occurrence, only above 4$.
All of the above,at your own discretion, your trading rules and your preferred trading strategies.
This is not a recommendation to buy / sell.
"Two Phase III multinational clinical trials are currently being conducted with our PLX-PAD product candidate: one in CLI, and the other in
muscle recovery following surgery for hip fracture. In April 2019, we successfully enrolled over 50% of patients in our Phase III study in CLI, which
allows for an interim analysis of efficacy after a one-year follow-up period under the European Medicines Agency’s, or EMA, Adaptive Pathways
pilot project, or the Adaptive Pathways Project, in which PLX-PAD was selected to participate In December 2019, we successfully enrolled 75% of
the patients and, based on our current patient enrollment progress, we expect to complete the follow up of our Phase III study in CLI in the first half
of 2020 with respect to the European adaptive pathway, and in the first half of 2021 with respect to the United States"
Technically, a good chance for pattern occurrence, only above 4$.
All of the above,at your own discretion, your trading rules and your preferred trading strategies.
This is not a recommendation to buy / sell.
交易开始:
Nice ...............